About
Coronis Partners is a leading Israeli Investment Company specializing in the biotechnology sector and focusing exclusively on highly select opportunities in the life sciences including therapeutics, diagnostic and agro-bio space. Coronis companies have demonstrated through superior management and financial planning - high growth, good financial stability and the ability to meet their development plans and goals. Since 2004, Coronis has invested over $10M in seven high quality portfolio companies. In 2007, four of Coronis companies issued public offerings BiondVax (TASE: BNDX) and Evogene (TASE: EVGN) in Tel Aviv; Rosetta Genomics (Nasdaq:ROSG) and Modigene (Nasdaq:MODG) at Nasdaq. Coronis performed partial exits in three of the four traded companies, with return on the initial price per share ranging between 5 to 6 fold in each of them (Evogene - Invested at $1 and Exited at $5; BiondVax - Invested at $0.45 and Exited at $2.26; Prolor - Invested at $1.5 and Exited at $8.6). The fifth company Glycominds has successfully completed a public offering in TASE in February 2011 (TASE: GLCM). Coronis Partners was active till the end of 2016.